Cambridge Healthtech Institute’s 13th Annual

Kinase Inhibitor Discovery

Emerging Targets, New Tools and Strategies, and Targeted Kinase Degraders

September 17-18, 2020

 

Kinase inhibitor discovery is a very active area as developers are exploring more deeply into designing immune-modulatory agents as single or combination therapies, tackling chronic disease indications such as inflammation and CNS disorders, as well as effectively harnessing allosteric modulators, and covalently binding compounds. This year we will also be discussing the role of artificial intelligence, new and non-oncology drug targets, phosphatases, and protein degraders in kinase development. Cambridge Healthtech Institute’s 13th Annual Kinase Inhibitor Discovery conference will once again bring together academic and industry leaders to network, collaborate, and discuss advances in kinase inhibitor discovery and development.

Preliminary Agenda

KINASE INHIBITOR DISCOVERY – AN OVERVIEW

Biochemical and Cellular Selectivity of all Clinically-Approved Kinases

Guido Zaman, PhD, Managing Director and Head of Biology, NTRC

INFORMATICS AND AI FOR KINASE DISCOVERY

Automation and Artificial Intelligence in Kinase Inhibitor Discovery

Istvan Enyedy, PhD, Director, Computational Chemistry, Black Diamond Therapeutics

Uncovering Novel Therapeutic Opportunities within the Dark Kinome

Shawn Gomez, EngScD, Professor, Biomedical Engineering/Pharmacology, UNC-Chapel Hill

Profiling HER2-Targeted Tyrosine Kinase Inhibitors to Identify Novel Treatment Indications

Neil Conlon, Researcher, Dublin City University

NON-ONCOLOGY INDICATIONS AND UNDERSTUDIED KINASES

Checkpoint Inhibition of Abl Kinase Can Functionally Reverse Neurodegenerative Disease

Milton Werner, PhD, President and CEO, Inhibikase Therapeutics, Inc.

Interaction of Substrates and Inhibitors with Tousled-Like Kinases

Benjamin Turk, PhD, Associate Professor, Department of Pharmacology, Yale University School of Medicine

 

Targeting BRAFV600E Dimers Using an Allosteric Site

Evris Gavathiotis, PhD, Professor, Biochemistry, Albert Einstein College of Medicine

FEATURED SESSION: INNOVATIVE PLATFORMS FOR CHALLENGING TARGETS

An Affinity-Directed PROtein Missile (AdPROM) System for Targeted Modification of Intracellular Proteins

Gopal Sapkota, PhD, Programme Leader, MRC Protein Phosphorylation and Ubiquitylation Unit, Sir James Black Centre, School of Life Sciences, University of Dundee

Large-Scale Proteomics Approaches to Enable Degrader Development for Challenging Targets in Cancer

Katherine Donovan, PhD, Scientist, Laboratory of Dr. Eric Fischer, Cancer Biology, Dana-Farber Cancer Institute/Harvard Medical School

Chemoproteomic Approaches to Interrogate the Degradable Kinome

Fleur Ferguson, PhD, Research Fellow, Cancer Biology, Dana-Farber Cancer Institute, Biological Chemistry and Molecular Pharmacology, Harvard Medical School

Talk Title to be Announced

Raghava Reddy Kethiri, PhD, CSO, Laxai Life Sciences Pvt. Ltd.




For more details on the conference, please contact:
Nandini Kashyap, MS

Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-972-5406
Email: nkashyap@healthtech.com

 

For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com